Vertex signs agreement to acquire Crinetics for $10bn
Vertex Pharmaceuticals has signed a definitive agreement to acquire Crinetics Pharmaceuticals for nearly $10 billion. This acquisition, expected to close in Q3 2026, will add two main endocrinology assets to Vertex's portfolio: Palsonify for acromegaly and atumelnant for congenital adrenal hyperplasia, projected to have a combined annual peak sales potential exceeding $5 billion. Vertex CEO Reshma Kewalramani highlighted the strategic fit due to Crinetics' focus on serious diseases with unmet needs and potentially transformative medicines.
Vertex (Nasdaq: VRTX) to acquire Crinetics (CRNX) in $10B cash deal
Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals for $10 billion in an all-cash deal, paying $85.00 per share. The acquisition will add Crinetics' FDA-approved acromegaly drug PALSONIFY and late-stage asset atumelnant to Vertex's portfolio, with potential for over $5 billion in combined annual revenue. The transaction, unanimously approved by both boards, is expected to close in the third quarter of 2026, subject to customary conditions.
Vertex Grows Its Rare Disease Business With $10bn Crinetics Buy
Vertex Pharmaceuticals is expanding its rare disease portfolio by acquiring Crinetics Pharmaceuticals for $10 billion. This acquisition adds a fifth business group, endocrine diseases, to Vertex's operations, following the recent US and EU approval of Crinetics' drug Palsonify for acromegaly. The move signals Vertex's strategic growth into new therapeutic areas beyond its established cystic fibrosis franchise.
Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Crinetics Pharmaceuticals (Nasdaq: CRNX) regarding potential breaches of fiduciary duty due to its recently announced transaction with Vertex. Shareholders are set to receive $85.00 per share in cash, totaling approximately $10.0 billion, and Ademi LLP is examining whether this constitutes a fair price for public shareholders, especially given that Crinetics insiders will receive substantial benefits. The investigation also scrutinizes the agreement's terms, including a significant penalty for competing bids and the conduct of Crinetics' board of directors.
Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) following its recently announced $10.0 billion transaction with Vertex. The investigation focuses on potential breaches of fiduciary duty by Crinetics' board of directors, particularly regarding the fairness of the $85.00 per share cash offer to public shareholders and the implications of change of control arrangements for insiders, as well as contractual limitations on competing bids. Shareholders are encouraged to contact Ademi LLP for more information about joining the investigation.
CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition
Shares of Crinetics Pharmaceuticals (CRNX) surged nearly 100% in after-hours trading after Vertex Pharmaceuticals (VRTX) announced its intention to acquire the company for approximately $10 billion. The acquisition, valuing Crinetics at $85 per share in cash, aims to strengthen Vertex's pipeline in endocrine disease treatments and is expected to contribute around $5 billion in annual revenue by 2029. Vertex plans to finance the deal with cash and debt, with the transaction anticipated to close later this year.
If You Invested $1,000 in Crinetics Pharmaceuticals (CRNX)
This article analyzes the historical performance of Crinetics Pharmaceuticals (CRNX) stock, detailing how a $1,000 investment would have grown over 1, 5, and since 2018. It provides a comprehensive overview of the company's focus on endocrine diseases, its FDA-approved drug PALSONIFY, and its pipeline of investigational candidates. The article also includes various financial metrics and a comparison of CRNX's annual returns.
Crinetics Pharmaceuticals Shares Rise After UBS Initiates Coverage
Crinetics Pharmaceuticals (CRNX) saw its shares increase by over 6% after UBS initiated coverage with a "Buy" rating. The analyst set a price target of $70.00, suggesting significant upside potential for the stock. This positive analyst action reflects growing confidence in the company's prospects.
Crinetics Pharmaceuticals (CRNX) Receives Buy Rating from UBS with $55 Target GuruFocus News
Crinetics Pharmaceuticals (CRNX) received a Buy rating from UBS with a $55 price target, despite a recent stock decline, due to anticipated success of its drug atumelnant and its flagship product, Palsonify. However, the company faces challenges including a low GF Score of 47/100, significant insider selling, and a high P/S ratio indicating potential overvaluation. Investors are advised to exercise caution due to these mixed signals.
UBS initiates Crinetics stock with buy rating, $55 price target
UBS has initiated coverage on Crinetics Pharmaceuticals Inc. (CRNX) with a buy rating and a price target of $55, citing potential upside from its current price of $38.68. The firm projects risk-adjusted peak sales of $2.0 billion for the company’s Phase 3 atumelnant in Congenital Adrenal Hyperplasia and $4.2 billion across four programs, highlighting Crinetics' strong balance sheet with more cash than debt. This positive outlook is supported by upcoming data readouts for atumelnant in CAH and Cushing’s Syndrome, and Palsonify in carcinoid syndrome, as well as positive reaffirmed ratings from other analysts.
Form 144 Crinetics Pharmaceuticals For: 2 July By Investing.com
This article from Investing.com reports on a Form 144 filing for Crinetics Pharmaceuticals (CRNX) on July 2. The filing is a regulatory notice indicating the intent to sell restricted securities. The article includes the stock symbol and notes a 9.18% increase for CRNX.
[144] Crinetics Pharmaceuticals, Inc. SEC Filing
This article reports on an SEC Form 144 filing by Crinetics Pharmaceuticals, Inc. (CRNX) for the proposed sale of 6,000 shares of common stock, valued at $232,080.00, through Morgan Stanley Smith Barney LLC. The filing was accepted by SEC EDGAR on July 2, 2026, at 04:29 PM and relates to restricted stock units acquired on June 7, 2024.
Jeff Knight to sell 44,925 shares at CRNX (NASDAQ: CRNX)
Jeff Knight has filed to sell 44,925 shares of Crinetics Pharmaceuticals (CRNX) stemming from an exercise of stock options, with a proposed sale date of July 2, 2026. The filing also indicates 2,495 Restricted Stock Units (RSUs) dated March 15, 2025, and details past 10b5-1 sales totaling 120,982 shares between April and May 2026. These transactions are routine disclosures related to insider stock activities.
CRNX Stock Climbs As ENDO 2026 Data Extends Bullish Run
Crinetics Pharmaceuticals Inc. (CRNX) stock has climbed by 6.58% following promising clinical trial results presented at ENDO 2026, extending a previous bullish run. Key drivers include positive two-year data for PALSONIFY in acromegaly, suggesting durable hormone control and manageable safety, as well as strong data for atumelnant in congenital adrenal hyperplasia. The company also benefited from a delayed competitor, giving PALSONIFY a longer market runway.
Crinetics Pharmaceuticals (CRNX) Receives Buy Rating from UBS with $55 Target
Crinetics Pharmaceuticals (CRNX) received a Buy rating from UBS with a $55 price target, despite a year-to-date share price decline. Analyst Ashwani Verma sees the current price as an entry point due to upcoming catalysts, particularly the potential success of atumelnant, an oral ACTH antagonist. However, the company has a low GF Score of 47/100, a high P/S ratio of 228.38, and has seen significant insider selling, suggesting potential risks for investors.
Crinetics stock wins new Buy at UBS (CRNX:NASDAQ)
UBS has initiated coverage on Crinetics Pharmaceuticals (CRNX) with a Buy rating and a 12-month price target of $55. This recommendation comes after a recent pullback in the stock, presenting what UBS considers an attractive entry point for investors. Shares of the San Diego-based pharmaceutical company traded higher following the news.
UBS initiates Crinetics stock with buy rating, $55 price target By Investing.com
UBS has initiated coverage on Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) with a buy rating and a $55 price target, citing significant upside potential despite a recent stock decline. The firm projects substantial risk-adjusted peak sales for Crinetics' pipeline, particularly its Phase 3 atumelnant in Congenital Adrenal Hyperplasia. Crinetics also recently presented positive data from phase 2 trials and held its annual meeting, while other analysts like Stifel, Citizens, and H.C. Wainwright have reiterated buy ratings with even higher price targets.
Crinetics Pharmaceuticals (CRNX) Is Up 6.9% After Promising Phase 2 Atumelnant And Paltusotine Data Release - Has The Bull Case Changed?
Crinetics Pharmaceuticals saw a 6.9% stock increase following promising Phase 2 data for both atumelnant and paltusotine, therapies for rare endocrine diseases. Atumelnant showed efficacy in congenital adrenal hyperplasia by reducing glucocorticoid use, while paltusotine demonstrated maintained disease control and tolerability in acromegaly over two years. These results reinforce the company's investment narrative for its oral endocrine drugs, though concerns about high cash burn and potential dilution for future funding remain.
Crinetics Pharmaceuticals to report Q2 2026 results on August 4
Crinetics Pharmaceuticals is scheduled to report its second-quarter 2026 financial results on August 4, 2026, after the market closes, followed by a conference call to discuss results and provide a business update. The company specializes in developing novel therapies for endocrine diseases by targeting G-protein coupled receptors, with its first commercial product PALSONIFY™ already approved for acromegaly. The article also mentions recent reiterations of Buy and Market Outperform ratings by analysts for Crinetics Pharmaceuticals.
Price to book forward of Crinetics Pharmaceuticals Inc – MUN:6Z4
This article provides financial information for Crinetics Pharmaceuticals Inc (MUN:6Z4), specifically focusing on its forward price-to-book ratio. The content indicates that the market was closed at the time of viewing, with no current trades. It also details that the content is provided by TradingView, using data from ICE Data Services and FactSet.
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
Crinetics Pharmaceuticals, Inc. announced it will report its second-quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. Company management will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a business update. The company is focused on developing therapies for endocrine diseases and related tumors, with its first commercial product PALSONIFY™ already approved.
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
Crinetics Pharmaceuticals, Inc. announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. Company management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Crinetics Pharmaceuticals is focused on developing and commercializing novel therapies for endocrine diseases and endocrine-related tumors.
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
Crinetics Pharmaceuticals, Inc. announced it will report its second-quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. The company will host a conference call at 4:30 p.m. ET to discuss the financial results and provide a business update, with details provided for domestic and international dial-in, as well as a webcast link. Crinetics Pharmaceuticals specializes in developing therapies for endocrine diseases and endocrine-related tumors.
Enterprise value to EBITDA forward of Crinetics Pharmaceuticals Inc – MUN:6Z4
The article provides financial data for Crinetics Pharmaceuticals Inc (MUN:6Z4), specifically focusing on its enterprise value to forward EBITDA. It highlights that no trades have occurred, and offers an overview of financials, news, documents, community discussions, forecasts, and seasonal trends for the company.
Price to earnings forward of Crinetics Pharmaceuticals, Inc. – NASDAQ:CRNX
This article provides a financial overview of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), focusing on its price-to-earnings forward metric. The content appears to be a stub or a section from a larger financial data platform, indicating key financial metrics for the company.
Enterprise value to revenue forward of Crinetics Pharmaceuticals, Inc. – BOATS:CRNX
This article provides financial information for Crinetics Pharmaceuticals, Inc. (CRNX) within the Blue Ocean Alternative Trade System (BOATS) platform. It focuses on the company's enterprise value to revenue forward metric. The content highlights the financial overview of CRNX and is part of a larger financial data service.
Crinetics Pharmaceuticals (CRNX) Draws Fresh Attention, Is The Valuation Gap Too Wide?
Crinetics Pharmaceuticals (CRNX) has garnered renewed investor attention due to recent trading activity. Despite a significant valuation gap where the stock's last closed price of $36.70 is well below a fair value near $82.43 according to a popular narrative, the company is still clinical-stage and loss-making, trading at a P/B ratio of 3x against an industry average of 2.2x. Investors are encouraged to assess the trade-offs between the company's potential and its inherent risks.
Price to sales forward of Crinetics Pharmaceuticals, Inc. – NASDAQ:CRNX
This article displays the "Price to sales forward" financial metric for Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) on the TradingView platform. The content is primarily a data placeholder, indicating the period, value, and change for this specific financial ratio for the company.
Enterprise value to revenue forward of Crinetics Pharmaceuticals, Inc. – NASDAQ:CRNX
This article provides financial data for Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), specifically focusing on its enterprise value to revenue forward metric. The information is presented within the context of TradingView's platform, indicating that it is likely a data point pulled from their financial analysis tools.
Price to sales forward of Crinetics Pharmaceuticals, Inc. – BOATS:CRNX
This article provides financial data for Crinetics Pharmaceuticals, Inc. (CRNX), focusing on its forward price-to-sales ratio. It appears to be a financial snapshot from TradingView, displaying basic company information and navigation options within the platform. The main content indicates a financial metric without further elaborated analysis.
Price to earnings forward of Crinetics Pharmaceuticals, Inc. – BOATS:CRNX
This article provides financial information for Crinetics Pharmaceuticals, Inc. (CRNX) focusing on its forward price-to-earnings ratio. It presents the company's ticker symbol on the Blue Ocean Alternative Trade System (BOATS) and indicates the market status. The content is primarily a data placeholder and navigational links for TradingView.
CRNX Stock Price Prediction 2025-2026 | Crinetics Pharmaceuticals Inc Forecast
24/7 Wall St. predicts a "BUY" rating for Crinetics Pharmaceuticals Inc (CRNX), setting a 12-month target price of $102.84, suggesting a 184.26% upside from its current price of $36.18. The forecast includes an optimistic scenario of $109.85 and a conservative one at $78.96. Long-term projections into 2031 and 2030 also indicate significant potential growth.
What Crinetics Pharmaceuticals (CRNX)'s New Endocrine Data Reveal About Its Emerging Rare-Disease Platform Potential
Crinetics Pharmaceuticals presented new clinical data at ENDO 2026 highlighting Phase 2 results for atumelnant in congenital adrenal hyperplasia and long-term data for PALSONIFY in acromegaly, reinforcing the company's potential beyond its current acromegaly focus. The data suggest a broader endocrine care platform, with atumelnant showing promise in reducing glucocorticoid doses. While optimistic analysts project significant revenue growth, investors are closely watching PALSONIFY's market uptake and the company's cash burn rate.
Crinetics Pharmaceuticals : CRNX
This article provides an overview of Crinetics Pharmaceuticals (CRNX), a clinical-stage company focused on developing treatments for rare endocrine diseases. It highlights the company's flagship product, paltusotine, and its pipeline targeting other endocrine disorders. The article also includes stock data for CRNX, noting a price target of $103, an increase of 178.4%.
Crinetics Pharmaceuticals Inc Actuals & Estimates (BX:CRNX)
This article provides an overview of Crinetics Pharmaceuticals Inc (CRNX) stock performance, financial actuals, and analyst estimates. Key information includes future price forecasts, upcoming earnings reports, historical earnings per share and revenue figures, and details on net income and EBITDA. It also confirms that CRNX does not currently pay dividends and provides employee count as of June 2026.
CRNX Stock Price Prediction 2025-2026 | Crinetics Pharmaceuticals Inc Forecast
24/7 Wall St. predicts a "BUY" rating for Crinetics Pharmaceuticals Inc (CRNX), setting a 12-month target price of $102.84, suggesting a 184.26% upside from its current price of $36.18. Wall Street analysts largely agree, with 94% rating the stock a Buy. Long-term projections extend to 2031, with a target price of $682.90, indicating significant potential growth.
CRNX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Crinetics Pharmaceuticals Inc (CRNX) stock, including analyst price targets and ratings. It details the company's financial performance, such as recent earnings per share and revenue, and previews upcoming earnings dates. Additionally, it offers information on CRNX's net income, EBITDA, employee count, and confirms that the company does not pay dividends.
What Crinetics Pharmaceuticals (CRNX)'s New Endocrine Data Reveal About Its Emerging Rare-Disease Platform Potential
Crinetics Pharmaceuticals recently presented new clinical data at ENDO 2026, showcasing positive Phase 2 results for atumelnant in congenital adrenal hyperplasia and long-term efficacy for PALSONIFY in acromegaly. These findings strengthen the company's investment narrative by highlighting pipeline potential beyond acromegaly, complementing PALSONIFY's recent EU approval, and suggesting multiple future endocrine revenue streams. However, investors remain watchful of PALSONIFY's uptake and cash burn, as heavy spending and slow early revenue could necessitate fresh capital.
Crinetics (CRNX) grants RSUs and stock options to board director
Crinetics Pharmaceuticals' director, Caren Deardorf, has been granted 5,925 restricted stock units (RSUs) and stock options for 9,730 shares of common stock. Both the RSUs and stock options vest 100% on the earlier of the first anniversary of the grant date (June 18, 2026) or the next annual stockholder meeting, contingent on her continued board service. Following these awards, Deardorf directly holds 22,225 shares of common stock and the new option position.
Crinetics (NASDAQ: CRNX) investors approve directors, auditor and say-on-pay
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) stockholders approved the election of three Class II directors, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and gave advisory approval for the compensation of named executive officers during their annual meeting on June 18, 2026. Approximately 97% of outstanding shares were represented at the meeting, indicating strong stockholder participation. All proposals presented received approval, with detailed voting results provided for each.
Crinetics (CRNX) director receives RSU and option grants in equity award
Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio received equity compensation on June 18, 2026, including 5,925 restricted stock units and options for 9,730 shares of common stock at an exercise price of $35.87 per share. These equity awards vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on his continued board service. Following these transactions, Rogerio directly holds 22,225 common shares and 9,730 stock options.
Form 4 Crinetics Pharmaceuticals Inc For: 22 June By Investing.com
This article announces the filing of Form 4 for Crinetics Pharmaceuticals Inc. on June 22nd, as reported by Investing.com. It is a brief, one-line piece of news, indicating an insider transaction report for the specified company. The content also includes various financial market data and popular news headlines, but the core focus is solely on the Form 4 announcement.
Crinetics (NASDAQ: CRNX) director receives new RSU and stock option grants
Crinetics Pharmaceuticals director Nichols Weston was granted 5,925 restricted stock units and stock options for 9,730 shares of common stock, with an exercise price of $35.87 per share. These equity awards, which vest on the earlier of one year from the grant date or the next annual meeting, are compensation for his board service. Following these grants, Weston directly holds 22,225 shares of Crinetics common stock.
[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity
Crinetics Pharmaceuticals director Matthew K. Fust received new equity awards for his board compensation, including 5,925 restricted stock units and stock options for 9,730 shares at an exercise price of $35.87. These awards are set to vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual shareholder meeting, contingent on his continued service. Following these transactions, Fust's direct holdings increased to 28,761 common shares.
Crinetics Pharmaceuticals shareholders approve board nominees and executive compensation
Crinetics Pharmaceuticals (NASDAQ:CRNX) shareholders have approved the election of three Class II directors to the board for three-year terms and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026. Additionally, shareholders cast an advisory vote in favor of the compensation for the company's named executive officers. The company's recent developments include optimistic analyst ratings and updates on its drug candidates, Palsonify and atumelnant, despite an indirect impact from potential delays related to Camarus.
Crinetics (CRNX) director receives new RSU and stock option awards
Crinetics Pharmaceuticals director Camille L. Bedrosian was granted 5,925 restricted stock units and stock options for 9,730 shares. These equity awards, which vest based on continued board service, were reported in a Form 4 SEC filing. Following these transactions, Ms. Bedrosian directly holds 22,225 shares of Common Stock and 9,730 options.
Form 8K Crinetics Pharmaceuticals Inc For: 22 June By Investing.com
This article announces the filing of a Form 8K by Crinetics Pharmaceuticals Inc. on June 22nd. The content appears to be a stub or placeholder, as it primarily consists of navigation and market data rather than detailed information about the Form 8K itself. The company's stock symbol CRNX is mentioned along with its performance on the day of publication.
Crinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data
Crinetics Pharmaceuticals (CRNX) recently presented new data at the ENDO 2026 meeting for its acromegaly drug PALSONIFY and investigational ACTH receptor antagonist atumelnant. Despite a mixed short-term share price performance, analysts suggest the stock could be 56.5% undervalued, with a fair value of $82.43 compared to its current trading price of $35.87. This undervaluation is largely based on expectations of aggressive revenue growth and rising margins, particularly driven by PALSONIFY's potential to expand acromegaly care.
Crinetics Pharmaceuticals Inc (CRNX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Crinetics Pharmaceuticals Inc (CRNX), detailing its volatility, financial risk metrics, and investment risk. CRNX has a risk assessment score of 5.66 and a beta of 0.33, indicating it tends to underperform during rising markets but experiences smaller declines in downturns. The report also highlights various performance metrics including maximum drawdown, volatility, and Sharpe ratios over different periods.
Crinetics Pharmaceuticals director Okey sells $246,142 of stock By Investing.com
Crinetics Pharmaceuticals director Stephanie Okey sold 6,900 shares of common stock for $246,142 through a predetermined trading plan. Following the sale, Okey holds 6,400 shares. The company has a fair financial health score, and its stock is trading near its fair value, with analysts setting higher price targets despite a recent Complete Response Letter for a manufacturing issue.
